首页|期刊导航|中国现代中药|网络药理学结合转录组测序探讨天舒胶囊对高尿酸血症肾病的干预作用机制

网络药理学结合转录组测序探讨天舒胶囊对高尿酸血症肾病的干预作用机制OA

Mechanism of Action of Tianshu Capsule in Intervening Hyperuricemic Nephropathy Based on Network Pharmacology and Transcriptome Sequencing

中文摘要英文摘要

目的:研究天舒胶囊对高尿酸血症肾病(HN)大鼠的改善作用,并初步探讨其作用机制.方法:将32 只大鼠随机平均分为对照组、模型组、天舒胶囊组、阳性药(别嘌醇)组;以次黄嘌呤灌胃和氧嗪酸钾腹腔注射诱导制备HN大鼠模型,天舒胶囊组和阳性药组分别连续灌胃 8 d,对照组和模型组给予等量的羟甲基纤维素钠溶液.采用HE染色检测大鼠肾脏病理变化情况;利用试剂盒检测大鼠血清中尿酸、肌酐、尿素氮的水平;通过网络药理学预测天舒胶囊改善高尿酸血症肾病作用的靶点和通路,并通过转录组学进一步探究其作用靶点和通路,最后运用逆转录实时荧光定量PCR(RT-qPCR)对大鼠肾脏中相关靶点的mRNA表达进行验证.结果:与对照组相比,模型组大鼠体质量减轻,肾脏指数显著升高,血清中尿酸、尿素氮、肌酐水平显著升高;与模型组相比,天舒胶囊组大鼠给药后体质量恢复,肾脏形态及肾脏指数改善,血清中尿酸、尿素氮、肌酐水平下降;网络药理学结合肾脏转录组学分析结果,表明天舒胶囊可能通过调控血清蛋白(ALB)、肿瘤坏死因子(TNF)、信号转导与转录激活因子 3(STAT 3)、白细胞介素-1β(IL-1β)、原癌基因(JUN)等靶点发挥改善高尿酸血症肾病的作用.RT-qPCR结果显示天舒胶囊具有抑制HN大鼠肾脏组织中TNF-α、IL-1β、JUN、细胞外调节激酶(ERK)、蛋白激酶B(Akt)、磷脂酰肌醇 3 激酶(PI3K)、p38 丝裂原活化蛋白激酶(MAPK)mRNA表达的作用.结论:初步证实了天舒胶囊具有改善高尿酸血症肾病的作用,其作用机制可能与调控TNF、IL-1β和JUN靶点的表达有关.

Objective:This paper aims to investigate the therapeutic effects of Tianshu Capsule on hyperuricemic nephropathy(HN)rats and to preliminarily explore its mechanisms of action.Methods:A total of 32 rats were randomly and evenly divided into a control group,a model group,a Tianshu Capsule group,and a positive drug(allopurinol)group.The HN rat model was induced and established by intragastric administration of hypoxanthine and intraperitoneal injection of potassium oxonate.The rats of the Tianshu Capsule group and the positive drug(allopurinol)group were intragastrically administered continuously for eight days,while those in the control group and the model group were given an equal amount of sodium carboxymethyl cellulose solution.HE staining was used to detect pathological changes in the kidneys of the rats.The levels of uric acid,creatinine,and urea nitrogen in rats'serum were measured using kits.Network pharmacology was employed to predict the action targets and pathways through which Tianshu Capsule ameliorated HN,and transcriptomics was further used to explore its action targets and pathways.Finally,reverse transcription-quantitative polymerase chain reaction(RT-qPCR)was used to verify the mRNA expression of relevant targets in the kidneys of the rats.Results:Compared with those in the control group,the rats in the model group exhibited a reduction in body weight,a significant increase in the kidney index,and significantly elevated levels of uric acid,urea nitrogen,and creatinine in the serum.In contrast to those in the model group,the rats in the Tianshu Capsule group showed recovery of body weight,improved kidney morphology and kidney index,and reduced levels of uric acid,urea nitrogen,and creatinine in the serum after administration.The analysis results of network pharmacology and renal transcriptomics showed that Tianshu Capsule can play a role in ameliorating HN by regulating albumin(ALB),tumor necrosis factor(TNF),signal transducer and activator of transcription 3(STAT3),interleukin-1β(IL-1β),Jun proto-oncogene,and other targets.RT-qPCR results further demonstrate that Tianshu Capsule inhibits the mRNA expression of tumor necrosis factor-α(TNF-α),IL-1β,JUN,extracellular regulated protein kinase(ERK),protein kinase B(Akt),phosphatidylinositol 3-kinase(PI3K),and p38 mitogen-activated protein kinase(p38MAPK)in the renal tissues of HN rats.Conclusion:This study preliminarily confirms that Tianshu Capsule has a therapeutic effect on HN,and its mechanism of action may be related to regulating the expression of targets,including TNF,IL-1β,and JUN.

张慧霖;周瑞;翁竞玉;杨远贵;史鑫波;唐志书;许洪波;陈世忠

陕西中医药大学 陕西中药资源产业化省部共建协同创新中心/陕西省创新药物研究中心,陕西 咸阳 712083陕西中医药大学 陕西中药资源产业化省部共建协同创新中心/陕西省创新药物研究中心,陕西 咸阳 712083陕西中医药大学 陕西中药资源产业化省部共建协同创新中心/陕西省创新药物研究中心,陕西 咸阳 712083陕西中医药大学 陕西中药资源产业化省部共建协同创新中心/陕西省创新药物研究中心,陕西 咸阳 712083陕西中医药大学 陕西中药资源产业化省部共建协同创新中心/陕西省创新药物研究中心,陕西 咸阳 712083陕西中医药大学 陕西中药资源产业化省部共建协同创新中心/陕西省创新药物研究中心,陕西 咸阳 712083||北京中医药大学,北京 100029陕西中医药大学 陕西中药资源产业化省部共建协同创新中心/陕西省创新药物研究中心,陕西 咸阳 712083陕西中医药大学 陕西中药资源产业化省部共建协同创新中心/陕西省创新药物研究中心,陕西 咸阳 712083||北京大学 药学院,北京 100191

医药卫生

天舒胶囊高尿酸血症肾病转录组学肿瘤坏死因子-α白细胞介素-1β原癌基因

Tianshu Capsulehyperuricemic nephropathytranscriptomicstumor necrosis factor-αinterleukin-1βJun proto-oncogene

《中国现代中药》 2026 (7)

1361-1370,中插10-中插12,13

国家自然科学基金项目(82174087)中医药"双链融合"中青年科研创新团队项目(2022-SLRH-YQ-005)

10.13313/j.issn.1673-4890.20251105005

评论